In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 3, 2011, Pages 273-280

  Brignole Baudouin, Françoise ^a,b,c,d,e   Riancho, Luisa ^a,b,c   Liang, Hong ^a,b,c,d   Nakib, Zaki ^a,b,c,d   Baudouin, Christophe ^a,b,c,d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CNRS   (France)

^d CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^e Centre Universitaire des Saints Pères   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; EYE DROPS; HOE 33342; LATANOPROST PLUS TIMOLOL; NEUTRAL RED; SUPEROXIDE; TIMOLOL PLUS TRAVOPROST;

APOPTOSIS; ARTICLE; CELL ASSAY; CELL VIABILITY; COMPARATIVE TOXICOLOGY; CONTROLLED STUDY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATIVE STRESS; SIDE EFFECT;

APOPTOSIS; BENZALKONIUM COMPOUNDS; CELL LINE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CLONE CELLS; CLOPROSTENOL; CONJUNCTIVA; DRUG COMBINATIONS; EPITHELIAL CELLS; HUMANS; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; OXIDATIVE STRESS; POLYMERS; PRESERVATIVES, PHARMACEUTICAL; PROSTAGLANDINS F, SYNTHETIC; SUPEROXIDES; SYMPATHOLYTICS; TIMOLOL;

EID: 79958834746     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2010.0111     Document Type: Article

References (31)

1. Schmier, J.K., Covert, D.W., and Robin, A.L. First-year treatment patterns among new initiators of topical prostaglandin analogs. Curr. Med. Res. Opin. 25:851-858, 2009.
2. Robin, A.L., and Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 112:863-868, 2005. (Pubitemid 40631506)
3. Robin, A.L., Novack, G.D., Covert, D.W., Crockett, R.S., and Marcic, T.S. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am. J. Ophthalmol. 144:533-540, 2007.
4. Chrai, S.S., Makoid, M.C., Eriksen, S.P., and Robinson, J.R. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J. Pharm. Sci. 63:333-338, 1974.
5. Leibowitz, H.M., and Kupferman, A. Drug interaction in the eye. Concurrent corticosteroid-antibiotic therapy for inflammatory keratitis. Arch. Ophthalmol. 95:682-685, 1977. (Pubitemid 8263113)
6. Sverrisson, T., Gross, R., Pearson, J., Rusk, C., and Adamsons, I. The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group. J. Glaucoma 8:315-324, 1999. (Pubitemid 32429169)
7. Baudouin, C. Allergic reaction to topical eyedrops. Curr. Opin. Allergy Clin. Immunol. 5:459-463, 2005. (Pubitemid 41345317)
8. Baudouin, C. The ocular surface in glaucoma. Cornea 28:S14-S19, 2009.
9. Baudouin, C., Labbe, A., Liang, H., Pauly, A., and Brignole- Baudouin, F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res. 29:312-334, 2010.
10. Brignole-Baudouin, F., Riancho, L., Liang, H., and Baudouin, C. Toxicological comparison of travoprost bak-free, travoprost bak-preserved, and latanoprost bak-preserved ophthalmic solutions in human conjunctival epithelial cells. Paper presented at: Tear Film & Ocular Surface (TFOS), Florence, Italy; Sept 22-25, 2010.
11. Liang, H., Brignole-Baudouin, F., Riancho, L., and Baudouin, C. In vivo assessment of the ocular surface effects of travoprost bak-free versus bak-preserved travoprost and latanoprost ophthalmic solutions. Paper presented at: Tear Film & Ocular Surface (TFOS), Florence, Italy; Sept 22-25, 2010.
12. Idziorek, T., Estaquier, J., De Bels, F., and Ameisen, J.C. YOPRO-1 permits cytofluorometric analysis of programmed cell death (apoptosis) without interfering with cell viability. J. Immunol. Methods 185:249-258, 1995.
13. Baudouin, C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 86:716-726, 2008.
14. Baudouin, C., Hamard, P., Liang, H., Creuzot-Garcher, C., Bensoussan, L., and Brignole, F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 111:2186-2192, 2004. (Pubitemid 39575587)
15. Baudouin,C., Riancho, L.,Warnet, J.M., and Brignole, F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest. Ophthalmol. Vis. Sci. 48:4123-4128, 2007. (Pubitemid 351261038)
16. Fechtner, R.D., Godfrey, D.G., Budenz, D., Stewart, J.A., Stewart, W.C., and Jasek, M.C. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 29:618-621, 2010.
17. Leung, E.W., Medeiros, F.A., and Weinreb, R.N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma 17:350-355, 2008.
18. Noecker, R.J., Herrygers, L.A., and Anwaruddin, R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23:490-496, 2004. (Pubitemid 38857008)
19. Pisella, P.J., Debbasch, C., Hamard, P., et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis. Sci. 45:1360-1368, 2004. (Pubitemid 38859312)
20. Liang, H., Baudouin, C., Pauly, A., and Brignole-Baudouin, F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br. J. Ophthalmol. 92:1275-1282, 2008.
21. Liang, H., Brignole-Baudouin, F., Rabinovich-Guilatt, L., et al. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol. Vis. 14:204-216, 2008. (Pubitemid 351223393)
22. Dutot, M., Pouzaud, F., Larosche, I., Brignole-Baudouin, F., Warnet, J.M., and Rat, P. Fluoroquinolone eye drop-induced cytotoxicity: role of preservative in P2X7 cell death receptor activation and apoptosis. Invest. Ophthalmol. Vis. Sci. 47:2812-2819, 2006. (Pubitemid 351639751)
23. Labbe, A., Pauly, A., Liang, H., et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium- 1: an experimental study. J. Ocul. Pharmacol. Ther. 22:267-278, 2006. (Pubitemid 44689667)
24. Ammar, D.A., Noecker, R.J., and Kahook, M.Y. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv. Ther. 27:837-845, 2010.
25. Katz, L.J. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J. Glaucoma 11:119-126, 2002. (Pubitemid 34298592)
26. Yamazaki, S., Nanno, M., Kimura, T., Suzumura, H., and Yoshikawa, K. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn. J. Ophthalmol. 54:7-14, 2010.
27. Uusitalo, H., Chen, E., Pfeiffer, N., et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol.88:329-336, 2010.
28. Baudouin, C., and de Lunardo, C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br. J. Ophthalmol. 82:39-42, 1998. (Pubitemid 28176961)
29. Barnebey, H.S., Orengo-Nania, S., Flowers, B.E., et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am. J. Ophthalmol. 140:1-7, 2005. (Pubitemid 41008083)
30. Schuman, J.S., Katz, G.J., Lewis, R.A., et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 140:242-250, 2005.
31. Palmberg, P., Kim, E.E., Kwok, K.K., and Tressler, C.S. A 12- week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur. J. Ophthalmol. 20:708-718, 2010.